188 related articles for article (PubMed ID: 29844393)
1. A fluorescence anisotropy assay to discover and characterize ligands targeting the maytansine site of tubulin.
Menchon G; Prota AE; Lucena-Agell D; Bucher P; Jansen R; Irschik H; Müller R; Paterson I; Díaz JF; Altmann KH; Steinmetz MO
Nat Commun; 2018 May; 9(1):2106. PubMed ID: 29844393
[TBL] [Abstract][Full Text] [Related]
2. Tubulin Maytansine Site Binding Ligands and their Applications as MTAs and ADCs for Cancer Therapy.
Cao S; Dong YH; Wang DF; Liu ZP
Curr Med Chem; 2020; 27(27):4567-4576. PubMed ID: 32175831
[TBL] [Abstract][Full Text] [Related]
3. Rhizoxin binding to tubulin at the maytansine-binding site.
Takahashi M; Iwasaki S; Kobayashi H; Okuda S; Murai T; Sato Y
Biochim Biophys Acta; 1987 Dec; 926(3):215-23. PubMed ID: 3120782
[TBL] [Abstract][Full Text] [Related]
4. [Inhibitors of tubulin assembly: specially on rhizoxin-maytansine site ligands].
Iwasaki S
Tanpakushitsu Kakusan Koso; 1993 Aug; 38(11):1742-52. PubMed ID: 8210422
[No Abstract] [Full Text] [Related]
5. Maytansine and cellular metabolites of antibody-maytansinoid conjugates strongly suppress microtubule dynamics by binding to microtubules.
Lopus M; Oroudjev E; Wilson L; Wilhelm S; Widdison W; Chari R; Jordan MA
Mol Cancer Ther; 2010 Oct; 9(10):2689-99. PubMed ID: 20937594
[TBL] [Abstract][Full Text] [Related]
6. A new tubulin-binding site and pharmacophore for microtubule-destabilizing anticancer drugs.
Prota AE; Bargsten K; Diaz JF; Marsh M; Cuevas C; Liniger M; Neuhaus C; Andreu JM; Altmann KH; Steinmetz MO
Proc Natl Acad Sci U S A; 2014 Sep; 111(38):13817-21. PubMed ID: 25114240
[TBL] [Abstract][Full Text] [Related]
7. Maytansine inhibits nucleotide binding at the exchangeable site of tubulin.
Huang AB; Lin CM; Hamel E
Biochem Biophys Res Commun; 1985 May; 128(3):1239-46. PubMed ID: 4004859
[TBL] [Abstract][Full Text] [Related]
8. Modeling the effects of drug binding on the dynamic instability of microtubules.
Hinow P; Rezania V; Lopus M; Jordan MA; Tuszyński JA
Phys Biol; 2011 Oct; 8(5):056004. PubMed ID: 21836336
[TBL] [Abstract][Full Text] [Related]
9. Binding of maytansine to tubulin: competition with other mitotic inhibitors.
Lin CM; Hamel E; Wolpert-DeFilippes MK
Res Commun Chem Pathol Pharmacol; 1981 Mar; 31(3):443-51. PubMed ID: 7255878
[TBL] [Abstract][Full Text] [Related]
10. Interactions of vinblastine and maytansine with tubulin.
Luduena RF; Anderson WH; Prasad V; Jordan MA; Ferrigni KC; Roach MC; Horowitz PM; Murphy DB; Fellous A
Ann N Y Acad Sci; 1986; 466():718-32. PubMed ID: 3460446
[No Abstract] [Full Text] [Related]
11. The interaction of spongistatin 1 with tubulin.
Bai R; Smith AB; Pettit GR; Hamel E
Arch Biochem Biophys; 2022 Sep; 727():109296. PubMed ID: 35594923
[TBL] [Abstract][Full Text] [Related]
12. Interaction of rhizoxin with bovine brain tubulin.
Sullivan AS; Prasad V; Roach MC; Takahashi M; Iwasaki S; Ludueña RF
Cancer Res; 1990 Jul; 50(14):4277-80. PubMed ID: 2364385
[TBL] [Abstract][Full Text] [Related]
13. Interaction of halichondrin B and homohalichondrin B with bovine brain tubulin.
Ludueña RF; Roach MC; Prasad V; Pettit GR
Biochem Pharmacol; 1993 Jan; 45(2):421-7. PubMed ID: 8435093
[TBL] [Abstract][Full Text] [Related]
14. βI-tubulin mutations in the laulimalide/peloruside binding site mediate drug sensitivity by altering drug-tubulin interactions and microtubule stability.
Kanakkanthara A; Rowe MR; Field JJ; Northcote PT; Teesdale-Spittle PH; Miller JH
Cancer Lett; 2015 Sep; 365(2):251-60. PubMed ID: 26052091
[TBL] [Abstract][Full Text] [Related]
15. Ado-Trastuzumab Emtansine Targets Hepatocytes Via Human Epidermal Growth Factor Receptor 2 to Induce Hepatotoxicity.
Yan H; Endo Y; Shen Y; Rotstein D; Dokmanovic M; Mohan N; Mukhopadhyay P; Gao B; Pacher P; Wu WJ
Mol Cancer Ther; 2016 Mar; 15(3):480-90. PubMed ID: 26712117
[TBL] [Abstract][Full Text] [Related]
16. High-content live-cell imaging assay used to establish mechanism of trastuzumab emtansine (T-DM1)--mediated inhibition of platelet production.
Thon JN; Devine MT; Jurak Begonja A; Tibbitts J; Italiano JE
Blood; 2012 Sep; 120(10):1975-84. PubMed ID: 22665936
[TBL] [Abstract][Full Text] [Related]
17. Ansamitocin P3 depolymerizes microtubules and induces apoptosis by binding to tubulin at the vinblastine site.
Venghateri JB; Gupta TK; Verma PJ; Kunwar A; Panda D
PLoS One; 2013; 8(10):e75182. PubMed ID: 24124473
[TBL] [Abstract][Full Text] [Related]
18. Effects of antimitotic agents on tubulin-nucleotide interactions.
Correia JJ
Pharmacol Ther; 1991 Nov; 52(2):127-47. PubMed ID: 1818332
[TBL] [Abstract][Full Text] [Related]
19. Binding of dolastatin 10 to tubulin at a distinct site for peptide antimitotic agents near the exchangeable nucleotide and vinca alkaloid sites.
Bai RL; Pettit GR; Hamel E
J Biol Chem; 1990 Oct; 265(28):17141-9. PubMed ID: 2211617
[TBL] [Abstract][Full Text] [Related]
20. Halichondrin B and homohalichondrin B, marine natural products binding in the vinca domain of tubulin. Discovery of tubulin-based mechanism of action by analysis of differential cytotoxicity data.
Bai RL; Paull KD; Herald CL; Malspeis L; Pettit GR; Hamel E
J Biol Chem; 1991 Aug; 266(24):15882-9. PubMed ID: 1874739
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
